2. PI3K/Akt/mTOR
  3. mTOR
  4. JR-AB2-011

JR-AB2-011 is a selective mTORC2 inhibitor with an IC50 value of 0.36 μM. JR-AB2-011 inhibits mTORC2 activity by blocking Rictor-mTOR association (Ki: 0.19 μM).JR-AB2-011 decreases the phosphorylation level of Akt, decreases MMP2 activity, thereby reducing the ability of tumor cells to migrate and invade. JR-AB2-011 also induces non-apoptotic cell death.

For research use only. We do not sell to patients.

CAS No. : 2411853-34-2

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 20 publication(s) in Google Scholar

JR-AB2-011 Related Antibodies

Top Publications Citing Use of Products

    JR-AB2-011 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 Jan 20;17(1):614.  [Abstract]

    Representative images of BODIPY staining in the indicated cells treated with Vehicle (DMSO), 50 μM JR-AB2-011 for 48 hours and 1 mM sodium citrate for 12 hours before harvest.

    JR-AB2-011 purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2025 Apr 22:S1535-6108(25)00138-2.  [Abstract]

    Relative proliferation of A375 cells treated with young adipocyte secretome (YA, blue) or YA with 500nM mTORC2 inhibitor JR-AB2-011 (YA+JR-AB2-011, white square with blue outline) or control (black) for 48 hours.

    JR-AB2-011 purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2025 Jan;27(1):73-86.  [Abstract]

    Immunofluorescence staining results of p21 cells in G1 phase RPE-1 cells after treatment with mTORC1/2 inhibitor INK-128 (0.2 μM), mTORC2 inhibitor JR-AB2-011 (5 μM), or mTORC1 inhibitor rapamycin (0.1 μM) for 24 hours.

    JR-AB2-011 purchased from MedChemExpress. Usage Cited in: J Extracell Vesicles. 2025 May;14(5):e70093.  [Abstract]

    WEHI-231-GFP cells were pretreated with Torin 1, rapamycin, JR-AB2-011 (0.1 µM), or DMSO for 15 minutes, then stimulated with anti-CD24 antibody or isotype control antibody for 15 minutes, followed by elution and co-culture with WEHI-303-tdTomato cells for 24 hours. The percentage of GFP and tdTomato double-positive cells was recorded after 24 hours of incubation.

    JR-AB2-011 purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 Nov 28:101844.  [Abstract]

    IB analysis was performed on three different GSCs (83, X01, and 528 cells) to detect the levels of p-S6K, p-AKT, S6K, AKT, ARHGAP1, BZW1, and BZW2, after these cells were treated with JR-AB2-011 for 24 hours.

    View All mTOR Isoform Specific Products:

    View All Isoforms
    mTOR mTORC1 mTORC2

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    JR-AB2-011 is a selective mTORC2 inhibitor with an IC50 value of 0.36 μM. JR-AB2-011 inhibits mTORC2 activity by blocking Rictor-mTOR association (Ki: 0.19 μM)[1].JR-AB2-011 decreases the phosphorylation level of Akt, decreases MMP2 activity, thereby reducing the ability of tumor cells to migrate and invade. JR-AB2-011 also induces non-apoptotic cell death[2].

    IC50 & Target[1]

    mTORC2

    0.36 μM (IC50)

    In Vitro

    JR-AB2-011 (10 µM - 250 µM; 48h) significantly reduces the survival rate and proliferation ability of different melanoma cell lines (MelJu, MelJuso, MelIm, B16)[2].
    JR-AB2-011 (50 µM, 250 µM; 48 h) decreases the phosphorylation level of Akt in MelIm cells, indicating that inhibition of mTORC2 attenuated the Ak t signaling pathway[2].
    JR-AB2-011 (50 µM, 250 µM; 48-78 h) results in a significant decrease in cell survival fraction SF and a significant reduction in the migration and invasive ability of melanoma cells, which is mainly achieved by decreasing MMP2 activity[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    JR-AB2-011 Related Antibodies

    Western Blot Analysis[2]

    Cell Line: MelJuso
    Concentration: 50 µM, 250 µM
    Incubation Time: 72h
    Result: JR-AB2-011 significantly reduced MMP2 protein and inhibited MMP2 activity, thereby inhibiting tumor cell invasion.
    In Vivo

    JR-AB2-011 (20 mg/kg; i.p.; daily) reduces the size and number of liver metastases in C57BL/6N mice with injection of B16 cells. No severe side effects or weight loss[2].
    JR-AB2-011 (4 mg/kg; p.o.; daily) significantly blocks the Dioscin-induced promotion of M2 macrophage polarization[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: C57BL/6N mice with injection of B16 cells [2].
    Dosage: 20 mg/kg everyday
    Administration: i.p.
    Result: JR-AB2-011 resulted in a significant decrease in hepatic tumor burden and metastasis load, as assessed by MRI and BLI.
    Histological analysis confirmed the presence of fewer and smaller metastases in the liver of treated mice. MMP2 expression was also significantly reduced.
    Animal Model: DSS (dextran sulfate sodium) induced colitis in mice [3]
    Dosage: 4 mg/kg; Dioscin 160 mg/kg; daily
    Administration: p.o.
    Result: JR-AB2-011 significantly blocked the Dioscin-induced promotion of M2 macrophage polarization.
    JR-AB2-011 inhibited the mTORC2/PPAR-γ signaling pathway, attenuating the regulatory effects of Dioscin on macrophage metabolism and polarization.
    The decrease in inflammation-related biomarkers (e.g., TNF-α, IL-6, IFN-γ, etc.) was partially reversed, indicating that the anti-inflammatory effects of Dioscin were suppressed.
    Molecular Weight

    398.28

    Formula

    C17H14Cl2FN3OS
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    ClC1=C(Cl)C=C(NC(N2/C(SC(C)C2)=N/C3=CC=C(F)C=C3)=O)C=C1
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvent & Solubility
    In Vitro: 

    DMSO : 62.5 mg/mL (156.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.5108 mL 12.5540 mL 25.1080 mL
    5 mM 0.5022 mL 2.5108 mL 5.0216 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (5.22 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.08 mg/mL (5.22 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 98.15%

    SDS (252 KB)

    COA (253 KB) LCMS (96 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.5108 mL 12.5540 mL 25.1080 mL 62.7699 mL
    5 mM 0.5022 mL 2.5108 mL 5.0216 mL 12.5540 mL
    10 mM 0.2511 mL 1.2554 mL 2.5108 mL 6.2770 mL
    15 mM 0.1674 mL 0.8369 mL 1.6739 mL 4.1847 mL
    20 mM 0.1255 mL 0.6277 mL 1.2554 mL 3.1385 mL
    25 mM 0.1004 mL 0.5022 mL 1.0043 mL 2.5108 mL
    30 mM 0.0837 mL 0.4185 mL 0.8369 mL 2.0923 mL
    40 mM 0.0628 mL 0.3138 mL 0.6277 mL 1.5692 mL
    50 mM 0.0502 mL 0.2511 mL 0.5022 mL 1.2554 mL
    60 mM 0.0418 mL 0.2092 mL 0.4185 mL 1.0462 mL
    80 mM 0.0314 mL 0.1569 mL 0.3138 mL 0.7846 mL
    100 mM 0.0251 mL 0.1255 mL 0.2511 mL 0.6277 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    JR-AB2-011 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    JR-AB2-0112411853-34-2mTORMammalian target of RapamycinC57BL/6N mice melanoma cellMMP2AktInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    JR-AB2-011
    Cat. No.:
    HY-122022
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.